Filana Therapeutics, Inc. (FLNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Filana Therapeutics, Inc. (FLNA) has a cash flow conversion efficiency ratio of -0.130x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.88 Million) by net assets ($68.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See FLNA net asset quality index to measure how much of total assets are equity-financed.
Filana Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Filana Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Filana Therapeutics, Inc. (FLNA) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Filana Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Filana Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Analabs Resources Bhd
KLSE:7083
|
-0.013x |
|
Edip Gayrimenkul Yatirim Sanayi ve Ticaret AS
IS:EDIP
|
0.008x |
|
Nyquest Technology Co Ltd
TWO:6494
|
0.090x |
|
Synergetic Auto Performance Public Company Limited
BK:ASAP
|
1.134x |
|
Mereo BioPharma Group PLC ADR
NASDAQ:MREO
|
-0.127x |
|
ESTsoft Corp
KQ:047560
|
-0.074x |
|
Klimasan Klima Sanayi ve Ticaret AS
IS:KLMSN
|
0.149x |
|
Maison Antoine Baud Société Anonyme
PA:MLMAB
|
N/A |
Annual Cash Flow Conversion Efficiency for Filana Therapeutics, Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of Filana Therapeutics, Inc. from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Filana Therapeutics, Inc. worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $74.40 Million | $-32.25 Million | -0.433x | +45.98% |
| 2024-12-31 | $145.70 Million | $-116.93 Million | -0.803x | -34.49% |
| 2023-12-31 | $137.47 Million | $-82.03 Million | -0.597x | -75.15% |
| 2022-12-31 | $227.54 Million | $-77.51 Million | -0.341x | -- |
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from… Read more